Scrip    Clinica    RAJ    Scrip Clinical Research    AnimalPharm
Email ID
Password
Forgotten your password?
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Cancer
|
Cardiovascular
|
Infection
|
Metabolic
|
Musculoskeletal
|
CNS
|
Respiratory
|
Gastrointestinal
|
Other
|
Therapy Sector - Gastrointestinal
EVENTS
Today
Berlin, Germany
Today
Berlin, Germany
22 March 2010
London, UK
JOB OF THE WEEK Promote your vacancy here
DIRECTORY Scrip Directory 2009
GSK's RLS setback has XenoPort halving workforce
09 March 2010
XenoPort is shedding 50% of its workforce and shelving its discovery research efforts following the "unexpected setback" in the approval of Horizant (XP13512; gabapentin enacarbil extended release tablets), which is under development with ...
AstraZeneca to exit specialist areas
03 March 2010
AstraZeneca is to stop research in several core areas as it strives to improve its R&D efficiency and cut costs. Newly released details of the restructuring, which was first revealed at its financial results meeting in January, show that it will ...
Pantoprazole produces mixed results for Nycomed
02 March 2010
Pantoprazole (Protonix) proved to be both a boon and blight on Nycomed 's financial performance in 2009. The gastro-oesophageal reflux disease treatment struggled to cope with its loss of exclusivity in many key European markets, but still drove ...
US FDA advisory panel backs Salix's Xifaxan for hepatic encephalopathy
24 February 2010
Salix Pharmaceuticals has won a strong endorsement from the US FDA's advisory committee on gastrointestinal drugs for approval of a new indication for its semi-synthetic antibiotic Xifaxan (rifaximin). On February 23rd, the panel voted 14 to four ...
Arrow acquisition boosts Watson's 2009 performance
24 February 2010
Watson Pharmaceuticals ' acquisition of Arrow in early December helped to boost its full-year 2009 net revenues to $2.8 billion, 10% higher than in 2008. The acquisition, which cost Watson $1.75 billion, particularly boosted Watson's generic ...
 
Market Insight - Differentiation guiding firms through maze of hepatitis C drug development
22 January 2010
The therapeutic landscape in HCV treatment is at an inflection point – recent data from the first generation of protease inhibitors promise the dawn of a new standard of care. But do not expect to ...
Challenges and opportunities in the Philippine pharma market
08 January 2010
On the face of it, the Philippines should be an attractive market for multinational pharmaceutical companies. There is a well-established healthcare system that covers the majority of the population ...
2010 Scrip 100 - Innovate to accumulate
09 December 2009
Drug delivery specialists continue to push the boundaries of innovative science, with recent highlights including the emergence of a needle-free migraine treatment and advances in RNAi delivery, ...
 
Revaprazan set to drive Yuhan's expansion
05 February 2009
The South Korean pharmaceutical company Yuhan Corp is looking to expand sales of its novel acid pump antagonist revaprazan into overseas markets as part of an effort to take group revenues past the ...
 
Questions linger over US comparative effectiveness funding
24 February 2009
The economic stimulus bill signed into law by US President Barack Obama on February 17th provides a $1.1 billion bolus to government agencies for comparative effectiveness research on medical ...
Life under FDAAA: Four months of post-approval studies and REMS
01 August 2008
The FDA has not hesitated to use its new safety powers since they took effect on March 25th. A review of original and supplemental NDA and BLA approval letters on the FDA's website indicates that, ...
 
Antisense inhibition of ICAM-1 expression as therapy provides insight into basic inflammatory pathways through early experiences in IBD
01 October 2008
Background: Alicaforsen (ISIS 2302), an antisense to intercellular adhesion molecule-1 (ICAM-1) (CD54), was designed to inhibit ICAM-1 expression. ICAM-1 seems to play a role in cell-mediated ...
Long-term treatment with infliximab in inflammatory bowel disease: safety and tolerability issues
01 September 2008
Crohn's disease and ulcerative colitis represent the most common forms of inflammatory bowel disease (IBD), clinical conditions affecting the small and/or large bowel. It is well known that IBD is an ...
Molecular diagnostics of primary biliary cirrhosis
01 June 2008
Background: Primary biliary cirrhosis (PBC) is an autoimmune liver disease of unknown etiology characterized by the presence of antimitochondrial antibodies (AMA) in 90 – 95% of patients. AMA are ...
 
COMPANY/ORGANISATION
CONDITION
GEOGRAPHY
DRUG
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Terms & Conditions
Privacy Policy
Sitemap
About Us
Advertise
Subscribe
Scrip
Clinica
RAJ
Scrip Clinical Research
Animal Pharm